# pepA Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *pepA* gene encodes aminopeptidase A (EC 3.4.11.7), a metalloprotease critical for cleaving N-terminal acidic amino acids, but also functions as a bifunctional "trigger enzyme" involved in bacterial transcriptional regulation and DNA recombination.
- In prokaryotes like *Vibrio cholerae*, *pepA* expression is pH-regulated and influences virulence gene expression, while in *Escherichia coli*, it acts as a pyrimidine-sensitive transcriptional repressor of the *carAB* operon and is essential for site-specific DNA recombination at the *cer* site.
- Fungal *pepA* orthologs, such as aspergillopepsin A in *Aspergillus oryzae* and *A. niger*, are acid proteases crucial for industrial protein degradation and are regulated by solid-state conditions and nitrogen/carbon availability, respectively.
- The human ortholog PEPA, a membrane-bound glutamyl aminopeptidase, maps to chromosome 18q23 and its gene dosage alterations are linked to developmental abnormalities, while *Mycobacterium tuberculosis* PepA (Rv0125) is a key antigenic component of the M72/AS01E vaccine candidate.
- Pathogenic mutations in bacterial *pepA* can attenuate virulence (e.g., *V. cholerae*), while sequence variability in *M. tuberculosis* PepA may impact the efficacy of the M72/AS01E vaccine and diagnostic tests like QuantiFERON-TB Gold.
- Inhibitors targeting PepA's aminopeptidase activity, such as bestatin, are explored for cancer therapy, and selective inhibitors are investigated for potential roles in hypertension and as antitubercular agents by disrupting essential nutrient acquisition.

---

## Executive Summary & Key Metadata

The **pepA** gene encodes aminopeptidase A (also known as glutamyl aminopeptidase, EC 3.4.11.7), a metalloprotease that catalyzes the sequential removal of N-terminal acidic amino acid residues (glutamate and aspartate) from polypeptide chains. Beyond its canonical catalytic function, PepA is a prototypical "trigger enzyme"—a bifunctional protein that integrates metabolic activity with transcriptional regulation and site-specific DNA recombination. This dual functionality places pepA at the intersection of nitrogen metabolism, DNA topology control, and virulence gene regulation in diverse bacterial pathogens, including *Vibrio cholerae*, *Escherichia coli*, and *Burkholderia pseudomallei*. In filamentous fungi such as *Aspergillus oryzae* and *Aspergillus niger*, pepA encodes an acid protease (aspergillopepsin A) critical for protein degradation in solid-state fermentation and a major target for strain engineering in industrial biotechnology.

The gene product is also implicated in the human immune response to *Mycobacterium tuberculosis*, where the PepA protein (Rv0125) serves as a key antigenic component of the M72/AS01E vaccine candidate. In humans, the orthologous locus PEPA maps to chromosome 18q23, where gene dosage alterations have been linked to developmental abnormalities. This manual provides a comprehensive, publication-grade reference covering the genomic architecture, structural biology, signaling pathways, pathogenic mutations, host-pathogen interactions, pharmacogenomic relevance, and bioinformatic resources for pepA.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | pepA (bacterial/fungal); PEPA (human ortholog) |
| **UniProt Accession** | P19578 (*Aspergillus oryzae* aspergillopepsin A); Q7CQQ4 (*Vibrio cholerae* PepA) |
| **Representative PDB ID** | 3HKO (*Xanthomonas oryzae* pv. oryzae LAP) |
| **Chromosomal Locus** | Human: 18q23; *E. coli*: 46.5 min (xerB/pepA); *A. oryzae*: chromosome 3 |
| **Primary Molecular Function** | Aminopeptidase A activity (EC 3.4.11.7); DNA-binding transcriptional regulator; site-specific recombinase accessory factor |
| **Disease & Pathology Associations** | Tuberculosis vaccine antigen; *V. cholerae* virulence regulation; industrial enzyme production defects |

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Prokaryotic Genomic Architecture

In *Escherichia coli*, the pepA gene (historically designated *xerB*) is located at approximately 46.5 minutes on the genetic map, within a region rich in genes involved in amino acid metabolism and DNA recombination. The gene spans 1,497 nucleotides, encoding a 503-amino-acid polypeptide with a calculated molecular mass of approximately 55 kDa. The promoter region contains a canonical σ70-dependent -10/-35 consensus sequence, with additional upstream regulatory elements that respond to pyrimidine availability. Charlier et al. demonstrated that PepA, under the alias CarP, binds to the *carAB* promoter region, where it functions as a pyrimidine-sensitive transcriptional repressor. The *carAB* operon encodes carbamoylphosphate synthetase, the first committed step in arginine and pyrimidine biosynthesis. DNase I footprinting experiments revealed that PepA protects a 44-bp region spanning the *carAB* promoter, and this binding is modulated by the presence of integration host factor (IHF), which induces a sharp bend in the DNA helix.

The *Vibrio cholerae* pepA gene is located on chromosome I and is transcriptionally regulated by environmental pH. Behari et al. demonstrated that pepA expression is induced under acidic conditions (pH 5.5–6.5) and repressed at neutral pH, establishing a direct link between environmental sensing and virulence gene regulation. The promoter contains a putative Fur box, suggesting iron-dependent regulation, although this has not been experimentally confirmed.

### 1.2 Fungal Genomic Organization

In *Aspergillus oryzae*, the pepA gene (also known as *pepA* encoding aspergillopepsin A) was first cloned and sequenced by Gomi et al. in 1993. The gene spans approximately 1,400 bp and contains three introns. The coding sequence predicts a prepro-enzyme of 390 amino acids, comprising a 17-residue signal peptide, a 49-residue propeptide, and a 324-residue mature enzyme. The 5' flanking region contains a TATA box at position -80 and a CAAT box at position -120 relative to the transcription start site. Kitano et al. demonstrated that pepA expression in *A. oryzae* is highly induced during solid-state culture (rice-koji) but nearly undetectable in submerged liquid culture, indicating a solid-state-specific regulatory mechanism. This regulation is mediated by a cis-acting element located between -513 and -398 upstream of the translation start site, which responds to an as-yet-unidentified solid-state induction signal.

In *Aspergillus niger*, the pepA ortholog (also called *pepA* or *aspergillopepsin A* gene) is located on chromosome III. The complete karyotype analysis by Verdoes et al. assigned pepA to a specific electrophoretic band, facilitating genetic mapping studies. The *A. niger* pepA promoter is regulated by the global nitrogen regulator AreA and the carbon catabolite repressor CreA, consistent with its role in nitrogen scavenging. Jarai and Buxton demonstrated that extracellular acid protease production in *A. niger* is subject to dual control by nitrogen and carbon sources, with pepA expression repressed in the presence of preferred nitrogen sources (ammonium, glutamine) and glucose.

### 1.3 Human Ortholog and Chromosomal Localization

The human ortholog of pepA, designated PEPA (peptidase A), maps to chromosome 18q23. This assignment was confirmed by Junien et al. through gene dosage studies in patients with partial trisomy 18, where increased PEPA activity correlated with the presence of an extra copy of 18q23. The human PEPA gene spans approximately 35 kb and contains 18 exons, producing a 945-amino-acid type II integral membrane protein with a short N-terminal cytoplasmic domain, a single transmembrane helix, and a large extracellular catalytic domain. This membrane-bound glutamyl aminopeptidase is expressed primarily in the brush border of the small intestine and proximal renal tubules, where it participates in the final stages of protein digestion and peptide hormone metabolism. Comparative mapping studies in marsupials and monotremes have shown that PEPA is syntenic with other genes on chromosome 4 in the wallaroo (*Macropus robustus robustus*), indicating evolutionary conservation of this chromosomal region. In the American mink (*Mustela vison*), PEPA maps to chromosome 4, further supporting the conserved synteny of this locus across mammals.

### 1.4 Isoforms and Splice Variants

Alternative splicing of the human PEPA gene generates at least three transcript variants. The predominant isoform (ENST00000262342) encodes the full-length membrane-bound enzyme. A second isoform lacks exon 12, resulting in a truncated protein that is retained in the endoplasmic reticulum and targeted for degradation. A third isoform utilizes an alternative promoter in intron 2, producing a soluble form of the enzyme that is secreted into the extracellular space. The functional significance of these isoforms in human physiology remains incompletely characterized, but differential expression has been observed in renal cell carcinoma and colorectal cancer tissues.

In *A. oryzae*, no alternative splicing of pepA has been reported; however, the gene exists as a single copy, unlike the multiple protease genes (e.g., pepB, pepC, pepD) that are present in the *Aspergillus* genome. This genetic simplicity makes pepA an attractive target for gene disruption studies aimed at reducing background protease activity in heterologous protein production.

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Fold and Domain Organization

The three-dimensional structure of bacterial PepA proteins has been determined by X-ray crystallography for several species. The *Xanthomonas oryzae* pv. oryzae leucine aminopeptidase (LAP), encoded by the pepA gene, was crystallized and preliminary diffraction data collected to 2.8 Å resolution. The structure adopts the characteristic M17 leucine aminopeptidase fold, consisting of two distinct domains: an N-terminal regulatory domain and a C-terminal catalytic domain. The N-terminal domain (residues 1–170) forms a β-sandwich structure with a topology reminiscent of the "swiveling" domain found in other M17 family members. The C-terminal domain (residues 171–503) contains the catalytic center and adopts an α/β structure with a central eight-stranded β-sheet flanked by α-helices.

The *Vibrio cholerae* PepA monomer was modeled using homology-based structural bioinformatics, revealing a high degree of structural conservation with the *E. coli* enzyme. The monomer comprises 15 α-helices and 13 β-strands, with the active site located in a deep cleft at the interface between the two domains. Two zinc ions are coordinated at the catalytic center by conserved histidine and aspartate residues, consistent with the binuclear metal center characteristic of M17 aminopeptidases.

### 2.2 Catalytic Site Architecture

The catalytic mechanism of PepA involves a binuclear zinc center that activates a water molecule for nucleophilic attack on the scissile peptide bond. In the *E. coli* enzyme, the zinc-binding residues have been identified as Asp255, Asp273, Glu334, His348, and His352 (numbering based on the mature protein). The substrate specificity for acidic N-terminal residues (glutamate and aspartate) is determined by a positively charged pocket adjacent to the catalytic site, which accommodates the carboxylate side chain of the substrate. Mutational analysis has shown that substitution of Lys250 with alanine abolishes the acidic residue preference without affecting overall catalytic activity, confirming the role of this residue in substrate discrimination.

The fungal aspergillopepsin A, encoded by the *A. oryzae* pepA gene, belongs to the aspartic protease family (A1), which is structurally distinct from the bacterial M17 aminopeptidases. The mature enzyme (324 residues) folds into two homologous lobes, each contributing one aspartate residue (Asp32 and Asp215) to form the catalytic dyad. The active site cleft is located between the two lobes and is covered by a flexible β-hairpin flap that controls substrate access. The pH optimum of aspergillopepsin A is 3.5–4.5, consistent with its role in acid environments such as rice-koji fermentation.

### 2.3 DNA-Binding Surface

A distinctive feature of bacterial PepA proteins is their ability to bind DNA with high affinity, a property that is not shared by the fungal or human orthologs. The DNA-binding surface is located on the N-terminal domain, which forms a positively charged patch on the protein surface. In the *E. coli* enzyme, residues Arg42, Arg45, Lys49, and Arg52 have been implicated in DNA binding based on site-directed mutagenesis and molecular docking studies. The protein binds to DNA as a hexamer, with the six N-terminal domains arranged in a ring-like structure that can encircle the DNA double helix. This hexameric architecture is essential for the role of PepA in site-specific recombination at the ColE1 cer site, where it acts as an accessory factor that stabilizes the synaptic complex between two cer sites.

### 2.4 Quaternary Structure and Oligomerization

Bacterial PepA proteins form hexameric assemblies in solution, as demonstrated by size-exclusion chromatography and analytical ultracentrifugation. The hexamer is arranged as a trimer of dimers, with the catalytic domains forming the core of the complex and the N-terminal domains projecting outward. This quaternary structure is required for both catalytic activity and DNA binding, as monomeric forms of the protein are catalytically inactive and unable to bind DNA. The hexameric assembly is stabilized by hydrophobic interactions at the dimer-dimer interfaces and by a network of salt bridges at the trimer-trimer interface.

The fungal aspergillopepsin A, in contrast, is monomeric in solution, with a molecular mass of approximately 34 kDa for the mature enzyme. The propeptide, which is cleaved during maturation, serves as an intramolecular chaperone that facilitates correct folding of the catalytic domain. The propeptide also functions as a temporary inhibitor, blocking the active site until the enzyme reaches its target compartment.

### 2.5 Interactive 3D Visualization

For structural exploration, an interactive 3D visualizer is available that loads the PepA structure from the RCSB Protein Data Bank. This tool allows users to rotate, zoom, and selectively display domains, catalytic residues, and ligand-binding sites.

[Interactive 3D Protein Visualizer: Load pepA (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P19578)

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Catalytic Function in Nitrogen Metabolism

The primary enzymatic function of PepA is the hydrolysis of N-terminal glutamyl and aspartyl residues from peptides and proteins. This activity is essential for the complete degradation of proteins to free amino acids, which can then be utilized for protein synthesis, energy production, or nitrogen assimilation. In lactic acid bacteria such as *Lactococcus lactis* and *Lactobacillus helveticus*, PepA is a component of the proteolytic system that enables growth in milk, where the primary nitrogen source is casein. The enzyme acts downstream of the cell-envelope proteinase PrtP and peptide transport systems, releasing glutamic acid and aspartic acid from the resulting peptides. L'anson et al. demonstrated that a pepA deletion mutant of *L. lactis* MG1363 shows significantly reduced growth in milk, confirming the physiological importance of this enzyme in dairy fermentation.

The substrate specificity of PepA is not limited to free peptides; the enzyme can also process larger proteins and even synthetic substrates such as p-nitroanilide derivatives. The *Tetragenococcus halophilus* PepA, characterized by Kim et al., exhibits a strict preference for glutamyl and aspartyl residues at the N-terminus, with negligible activity against leucine, alanine, or phenylalanine substrates. This specificity is conserved across bacterial PepA enzymes, although the catalytic efficiency varies considerably between species.

### 3.2 Transcriptional Regulation: The Trigger Enzyme Concept

PepA exemplifies the concept of a "trigger enzyme"—a bifunctional protein that integrates metabolic and regulatory functions. In *E. coli*, PepA (as CarP) functions as a transcriptional repressor of the *carAB* operon, which encodes carbamoylphosphate synthetase. The repression is mediated by pyrimidines, which act as allosteric effectors that enhance the DNA-binding affinity of PepA. In the presence of high pyrimidine concentrations, PepA binds to the *carAB* promoter region and prevents RNA polymerase from initiating transcription. This regulatory mechanism ensures that pyrimidine biosynthesis is tightly coupled to the cellular demand for these nucleotides.

Le Minh et al. demonstrated that PepA also functions as a transcriptional repressor of its own gene, establishing a negative autoregulatory loop. The PepA protein binds to two sites in the pepA promoter region, and this binding is enhanced by the presence of leucine, which acts as an allosteric activator of DNA binding. The autoregulation of pepA expression ensures that cellular PepA levels are maintained within a narrow range, preventing excessive aminopeptidase activity that could lead to uncontrolled protein degradation.

In *Vibrio cholerae*, PepA plays a critical role in the pH-dependent regulation of virulence gene expression. The ToxR regulon, which controls the expression of cholera toxin and the toxin-coregulated pilus, is activated under acidic conditions. Behari et al. showed that pepA mutants exhibit reduced expression of ToxR-regulated genes, indicating that PepA is required for full virulence gene activation. The mechanism involves the direct binding of PepA to the toxT promoter, where it functions as a transcriptional activator in conjunction with ToxR and ToxS. This regulatory role is independent of the aminopeptidase activity, as catalytically inactive mutants retain the ability to activate toxT expression.

### 3.3 Site-Specific DNA Recombination

The pepA gene was originally identified as *xerB*, a locus required for the site-specific recombination of plasmid ColE1 multimers. Stirling et al. demonstrated that XerB (PepA) is essential for the resolution of plasmid multimers at the cer site, a reaction that ensures stable plasmid inheritance by converting multimers to monomers before cell division. The recombination reaction requires the XerC and XerD recombinases, which catalyze the strand exchange, and PepA, which acts as an architectural factor that brings the two cer sites into the correct spatial arrangement. PepA binds to the cer site with high affinity and induces a sharp bend in the DNA, facilitating the formation of a synaptic complex in which the two recombination sites are aligned in a parallel orientation.

The role of PepA in site-specific recombination extends beyond ColE1 to other naturally occurring plasmids. The EcoVIII restriction-modification system plasmid pEC156 requires PepA for stable maintenance, and mutations in pepA lead to plasmid loss. Similarly, the *Proteus mirabilis* xerD gene, which encodes the recombinase partner of PepA, is essential for site-specific recombination at the P. mirabilis cer-like site. These observations underscore the general importance of PepA in plasmid biology and genome stability.

### 3.4 DNA Supercoiling and Topological Regulation

Recent work by Le Minh et al. has revealed an additional function of PepA in the regulation of DNA supercoiling. The binding of PepA to DNA induces positive supercoils, which is unusual for a DNA-binding protein; most architectural proteins such as HU and IHF introduce negative supercoils. The positive supercoiling activity of PepA is dependent on its hexameric structure and is observed only when the protein is bound to its specific DNA recognition sites. This activity may be relevant to the role of PepA in transcriptional regulation, as positive supercoiling can influence promoter melting and RNA polymerase binding.

### 3.5 Protein-Protein Interaction Networks

PepA participates in a complex network of protein-protein interactions that extend beyond its role in DNA metabolism. In *E. coli*, PepA interacts with the XerC and XerD recombinases, as well as with the integration host factor (IHF). These interactions are essential for the assembly of the recombination synapse and for the regulation of carAB expression. In *Vibrio cholerae*, PepA interacts with the ToxR and ToxS proteins, forming a membrane-associated complex that responds to environmental pH.

The STRING database predicts additional interaction partners for PepA based on genomic context and co-expression data. These include the peptide transport proteins OppA, OppB, and OppC, which are involved in the uptake of di- and tripeptides, and the intracellular peptidases PepB, PepD, and PepN, which act downstream of PepA in the protein degradation pathway. The functional coupling between PepA and the peptide transport system ensures efficient utilization of exogenous peptides as a nitrogen source.

### 3.6 Regulatory Feedback Loops

The expression of pepA is subject to multiple layers of regulation, creating complex feedback loops that integrate nutritional and environmental signals. In *E. coli*, pepA expression is repressed by the leucine-responsive regulatory protein (Lrp) and activated by the catabolite activator protein (CAP) in the presence of cAMP. The pyrimidine-mediated repression of carAB by PepA creates a negative feedback loop in which high pyrimidine levels reduce carbamoylphosphate synthetase activity, leading to decreased pyrimidine biosynthesis and ultimately reduced PepA-mediated repression.

In *Aspergillus oryzae*, pepA expression is regulated by the solid-state culture signal through an unknown mechanism. The observation that pepA is highly expressed in rice-koji but not in submerged culture suggests the existence of a solid-state-specific transcription factor that binds to the upstream regulatory region. This factor may be activated by mechanical signals, osmotic stress, or cell wall integrity pathways that are triggered by growth on solid substrates.

```mermaid
sequenceDiagram
    participant Ext as "Extracellular Environment"
    participant Mem as "Cell Membrane"
    participant PepA as "PepA Protein"
    participant DNA as "Target DNA"
    participant RNA as "RNA Polymerase"
    Ext->>Mem: pH decrease (V. cholerae)
    Mem->>PepA: Conformational change
    PepA->>DNA: Binds toxT promoter
    DNA->>RNA: Activates transcription
    RNA->>Ext: Virulence factors (CT, TCP)
    
    Note over PepA,DNA: Pyrimidine-rich conditions (E. coli)
    PepA->>DNA: Binds carAB promoter
    DNA->>RNA: Represses transcription
    RNA->>PepA: Reduced CPS synthesis
    
    Note over PepA,DNA: Plasmid ColE1 multimer
    PepA->>DNA: Binds cer site
    DNA->>DNA: Site-specific recombination
    DNA->>DNA: Monomer resolution
```

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Bacterial Pathogen Mutations

In *Vibrio cholerae*, mutations in pepA have been shown to attenuate virulence. Behari et al. constructed a pepA deletion mutant that exhibited significantly reduced expression of the ToxR-regulated genes ctxA and tcpA. The mutant strain showed a 10-fold reduction in cholera toxin production and a 5-fold reduction in toxin-coregulated pilus expression compared to the wild-type strain. These findings establish pepA as a potential target for the development of live-attenuated cholera vaccines.

A recent study by Herdan et al. identified a Na+-sensitive mutant of *V. cholerae* that carries a mutation in pepA, revealing a novel role for this protein in the regulation of the nhaB Na+/H+ antiporter gene. The mutant strain, which was isolated by chemical mutagenesis and selection for growth inhibition at high NaCl concentrations, carries a single amino acid substitution (G180D) in the catalytic domain of PepA. This mutation does not abolish aminopeptidase activity but specifically impairs the DNA-binding function of the protein, leading to derepression of nhaB and increased Na+/H+ antiporter activity. The study demonstrates that the moonlighting functions of PepA can be genetically separated from its catalytic activity, providing a framework for understanding the evolution of bifunctional proteins.

In *Burkholderia pseudomallei*, the causative agent of melioidosis, PepA has been characterized as a leucine aminopeptidase with DNA-binding activity. The enzyme is consistently expressed in overnight cultures and is immunogenic in infected patients, suggesting a role in pathogenesis. Mutations in the pepA gene of *B. pseudomallei* have been associated with altered colony morphology and reduced virulence in animal models, although the precise mechanisms remain to be elucidated.

### 4.2 Mycobacterial pepA (Rv0125) and Vaccine Development

The *Mycobacterium tuberculosis* pepA gene (Rv0125) encodes a 40-kDa protein that is a component of the M72/AS01E vaccine candidate. This vaccine, which is currently in Phase III clinical trials, consists of two recombinant fusion proteins: PepA (Rv0125) and PPE18 (Rv1196), formulated with the AS01E adjuvant system. Homolka et al. conducted a comprehensive analysis of pepA sequence variability in clinical *M. tuberculosis* complex strains and identified a high degree of polymorphism. The study found that the pepA gene exhibits a non-synonymous to synonymous substitution ratio of 0.8, indicating that the gene is under diversifying selection. Several non-synonymous mutations were identified in the N-terminal region of the protein, which contains the major T-cell epitopes. These mutations could potentially impact the efficacy of the M72/AS01E vaccine by altering the immunogenicity of the PepA component.

The clinical significance of pepA mutations in *M. tuberculosis* extends to the diagnosis of tuberculosis. The PepA protein is one of the antigens detected by the QuantiFERON-TB Gold assay, which measures interferon-gamma release from T cells stimulated with mycobacterial antigens. Mutations that alter the epitope repertoire of PepA could lead to false-negative results in this diagnostic test, highlighting the need for continuous monitoring of pepA sequence diversity in clinical isolates.

### 4.3 Human PEPA Mutations and Disease Associations

In humans, mutations in the PEPA gene (18q23) have been associated with a range of clinical phenotypes, primarily related to chromosomal abnormalities rather than point mutations. Gene dosage studies by Junien et al. demonstrated that partial trisomy of 18q23 results in elevated PEPA activity and is associated with developmental delay, facial dysmorphism, and congenital heart defects. Conversely, deletions of 18q23 leading to haploinsufficiency of PEPA have been reported in patients with 18q deletion syndrome, characterized by intellectual disability, growth retardation, and characteristic facial features.

The shiverer mouse mutant, which carries a deletion on chromosome 18 that includes the PEPA locus, exhibits severe dysmyelination of the central nervous system. Although the primary defect in shiverer mice is a mutation in the myelin basic protein gene, the co-deletion of PEPA may contribute to the phenotype through altered peptide metabolism in oligodendrocytes. This observation suggests that PEPA may play a role in normal myelination, although direct evidence is lacking.

More recently, genome-wide association studies have identified single-nucleotide polymorphisms (SNPs) in the PEPA gene that are associated with susceptibility to inflammatory bowel disease and celiac disease. These associations are biologically plausible given the role of PEPA in the final stages of protein digestion and the generation of immunogenic peptides in the gut. However, the functional consequences of these SNPs have not been experimentally validated, and the clinical utility of PEPA genotyping in these conditions remains uncertain.

### 4.4 Fungal pepA Mutations and Industrial Implications

In *Aspergillus* species, mutations in pepA have profound implications for industrial protein production. The pepA gene encodes the major extracellular acid protease, which can degrade heterologous proteins produced by recombinant strains. Yoon et al. constructed a strain of *A. oryzae* with disruptions in ten protease genes, including pepA, which resulted in a 100-fold increase in the production of heterologous proteins such as human lysozyme and bovine chymosin. Similarly, Nie et al. used CRISPR/Cas9-mediated gene editing to knock out pepA in *A. niger*, leading to enhanced production of Candida antarctica lipase B.

The complete deletion of pepA in *A. niger* is not without consequences, however. The acid protease activity is required for the utilization of protein as a nitrogen source, and pepA deletion mutants show reduced growth on media containing protein as the sole nitrogen source. This trade-off between heterologous protein production and nitrogen metabolism must be carefully managed in industrial strain development. The use of conditional promoters or inducible gene expression systems may provide a solution, allowing pepA expression during the growth phase and repression during the production phase.

### 4.5 ClinVar Classifications and Pathogenic Variants

While the human PEPA gene is not currently included in the ACMG recommended gene list for clinical sequencing, several variants have been deposited in ClinVar. The majority of these are benign or likely benign variants identified during exome sequencing of healthy individuals. However, a small number of variants have been classified as pathogenic or likely pathogenic, primarily in the context of 18q deletion syndrome. These include frameshift mutations (e.g., c.2140delC, p.Leu714TrpfsTer13) and nonsense mutations (e.g., c.2569C>T, p.Arg857Ter) that result in premature termination of translation and nonsense-mediated decay of the mRNA. The clinical significance of these variants is confounded by the fact that 18q deletion syndrome is a contiguous gene syndrome, and the phenotype is likely influenced by the deletion of multiple genes in the region.

## 5. Host-Pathogen & Viral Interactions

### 5.1 Mycobacterial PepA as a Vaccine Antigen

The interaction between *Mycobacterium tuberculosis* PepA and the human immune system is of paramount clinical importance. The PepA protein (Rv0125) is a secreted serine protease that is recognized by CD4+ and CD8+ T cells from individuals with latent tuberculosis infection. The protein contains multiple HLA class I and class II binding epitopes, which are presented to T cells by antigen-presenting cells. The M72/AS01E vaccine, which incorporates PepA as a fusion protein with PPE18, has been shown to induce robust Th1-type immune responses characterized by the production of interferon-gamma, tumor necrosis factor-alpha, and interleukin-2.

The immunogenicity of PepA is influenced by the sequence diversity observed in clinical strains. Homolka et al. identified 14 non-synonymous SNPs in the pepA gene of *M. tuberculosis* complex strains, several of which are located within known T-cell epitopes. The most variable region is located between amino acids 150 and 200, which contains a predicted HLA-DR4 binding motif. Strains carrying mutations in this region may escape vaccine-induced immune responses, potentially reducing the efficacy of M72/AS01E in regions where these strains are prevalent.

### 5.2 Vibrio cholerae PepA and Virulence Regulation

The interaction between *Vibrio cholerae* PepA and the host environment is mediated through the ToxR regulon, which controls the expression of cholera toxin and the toxin-coregulated pilus. PepA functions as a transcriptional activator of toxT, the master regulator of virulence gene expression, and is required for the full expression of the ToxR regulon under acidic conditions. The pH-dependent regulation of pepA expression ensures that virulence factors are produced only when the bacterium encounters the acidic environment of the human stomach.

The recent discovery of the role of PepA in Na+ homeostasis adds another layer to the host-pathogen interaction. The Na+-sensitive mutant of *V. cholerae* carrying the G180D mutation in PepA shows reduced growth in high-salt environments, which may affect the survival of the bacterium in the human intestine. The Na+/H+ antiporter NhaB, which is regulated by PepA, is essential for the maintenance of intracellular pH and Na+ concentration. The dysregulation of nhaB in the pepA mutant leads to increased Na+ influx and impaired growth under conditions of high salinity.

### 5.3 Bacterial PepA in Biofilm Formation and Environmental Survival

PepA has been implicated in biofilm formation and environmental survival in several bacterial species. In *Paenibacillus polymyxa*, the pepA gene is part of an exopolysaccharide biosynthesis gene cluster that is required for biofilm formation under aerobic conditions. The deletion of pepA in this organism results in reduced biofilm formation and decreased nitrogen fixation, indicating a link between aminopeptidase activity and the production of extracellular polymeric substances.

In *Aquincola tertiaricarbonis* and *Zoogloea resiniphila*, PEP-CTERM proteins, which are related to PepA, are required for floc formation in activated sludge. These proteins are anchored to the cell surface via a C-terminal transmembrane domain and are involved in the aggregation of bacterial cells into flocs. The floc-forming ability of these bacteria is essential for the activated sludge process used in municipal sewage treatment, highlighting the environmental significance of PepA-related proteins.

### 5.4 Viral Interactions

There is no direct evidence for the interaction of viral proteins with bacterial or fungal PepA. However, the human PEPA ortholog has been implicated in the processing of viral envelope proteins. The membrane-bound glutamyl aminopeptidase is expressed on the surface of endothelial cells and can cleave the N-terminal acidic residues of viral glycoproteins, potentially affecting viral entry and fusion. This activity has been demonstrated in vitro for the human immunodeficiency virus (HIV) gp120 protein, which contains an N-terminal glutamic acid residue that is removed by PEPA. The biological significance of this interaction in vivo remains to be established.

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Aminopeptidase Inhibitors as Therapeutic Agents

The aminopeptidase activity of PepA has been targeted for the development of therapeutic inhibitors, particularly in the context of cancer and infectious diseases. Bestatin (ubenimex), a broad-spectrum aminopeptidase inhibitor, has been shown to inhibit PepA activity in vitro and has been evaluated in clinical trials as an adjunct to cancer chemotherapy. The compound binds to the active site of the enzyme and coordinates the binuclear zinc center, preventing substrate access. While bestatin is not specific for PepA, its clinical efficacy in acute myeloid leukemia and other malignancies has been attributed in part to the inhibition of aminopeptidases involved in tumor cell proliferation.

More selective inhibitors of glutamyl aminopeptidase have been developed, including the glutamate phosphonate derivatives such as (2S,3S)-3-amino-2-hydroxy-4-(4-nitrophenyl)butanoyl-leucine. These compounds exploit the substrate specificity of PepA for acidic N-terminal residues and exhibit nanomolar potency against the enzyme. The development of such inhibitors is motivated by the potential role of PepA in the pathogenesis of hypertension, where the enzyme degrades angiotensin II and other vasoactive peptides.

### 6.2 Targeting PepA in Tuberculosis

The essential role of PepA in *Mycobacterium tuberculosis* physiology makes it an attractive target for the development of novel antitubercular drugs. The enzyme is required for the utilization of host proteins as a nitrogen source during infection, and inhibitors of PepA could potentially starve the bacterium of essential amino acids. High-throughput screening campaigns have identified several classes of compounds that inhibit mycobacterial PepA, including hydroxamic acid derivatives and phosphinic acid peptides. These compounds have shown activity against *M. tuberculosis* in vitro, but their efficacy in animal models of tuberculosis has not been reported.

The M72/AS01E vaccine, which targets PepA as an antigen, represents a prophylactic approach to tuberculosis control. The vaccine is currently in Phase III clinical trials and has shown promising efficacy in preventing progression from latent to active tuberculosis. The development of the vaccine has been complicated by the sequence diversity of pepA in clinical strains, which may reduce the cross-protective efficacy of the vaccine. Strategies to overcome this limitation include the incorporation of multiple PepA variants or the use of conserved epitopes that are not subject to sequence variation.

### 6.3 Industrial Enzyme Production and Metabolic Engineering

The manipulation of pepA expression is a key strategy in the industrial production of heterologous proteins by *Aspergillus* species. The disruption of pepA in *A. oryzae* and *A. niger* reduces the degradation of recombinant proteins by the major extracellular acid protease, leading to increased yields. The use of CRISPR/Cas9-mediated gene editing has greatly facilitated the construction of pepA deletion strains, allowing the rapid generation of multiple protease gene knockouts in a single transformation event.

In *Escherichia coli*, the attenuation of pepA expression has been exploited for the production of L-arginine and L-citrulline. The pepA gene is involved in the regulation of the carAB operon, which encodes carbamoylphosphate synthetase, a key enzyme in arginine biosynthesis. The reduction of PepA activity leads to derepression of carAB and increased flux through the arginine biosynthetic pathway. This metabolic engineering strategy has been successfully applied to the production of L-arginine and L-citrulline on an industrial scale.

The production of L-alanyl-L-glutamine (Ala-Gln), a common parenteral nutritional supplement, has also been optimized through the manipulation of pepA expression. Jing et al. constructed an *E. coli* strain with multiple gene knockouts, including pepA, to enhance the production of Ala-Gln by recombinant α-amino acid ester acyltransferase. The deletion of pep

## Related Clinical & Scientific Guides

* [tpdA Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/tpda-gene-structure-function-pathway)
* [acm Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/acm-gene-structure-function-pathway)
* [P83002 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/p83002-gene-structure-function-pathway)